Genkyotex raises $26M in Series C round extension

Monday, July 9, 2012 04:01 PM

Genkyotex, a Swiss developer of NOX inhibitors to treat oxygen-radical mediated diseases, has closed a $26 million extension to its Series C financing. Investors in the Series C round, including Eclosion, Edmond de Rothschild Investment Partners, Vesalius Biocapital Partners, MP Healthcare Venture, all participated in the financing extension.

Proceeds from the round will be used to advance clinical development of Genkyotex's lead compound, the NOX1/4 inhibitor GKT137831, through phase II development for the treatment of diabetic nephropathy and to progress pipeline molecules targeting different diseases. Results from initial single-dose phase Ia studies suggest that GKT137831 is safe and well tolerated. The ongoing multi-dose phase Ib study is expected to finish later this quarter.

"Since our last closing, Genkyotex has delivered on several important milestones, not least of which is producing initial first human data for our lead product GKT137831," said Ursula Ney, CEO of Genkyotex. "Meeting these milestones has ensured the continued support from our investors as illustrated by this large financing, which will fund the phase II in diabetic nephropathy, due to start towards the end of 2012."

Gilles Nobécourt, partner at Edmond de Rothschild Investment Partners, added, "With the start of clinical trials, Genkyotex has demonstrated its clear leadership position in the NOX field. We believe targeting NOX is very promising, with many potential therapeutic applications. Clinical evaluation of GKT137831 is the first step towards validating this entirely new class of therapeutic agents."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 8

Physicians: Manufacturers, success of clinical trials influence their decision to prescribe biosimilars

Pivotal trial results of Novartis chronic heart failure drug exceed expectations, could set new standard of care

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs